1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Whan In Pharmaceutical Co., Ltd.

Whan In Pharmaceutical Co., Ltd.

KKRX:016580
10,210.00
KRW
-150.00
(-1.45%)
1,155.36EPS
8.41P/E
179.66BMarket Cap
Oct 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6,843.44
7,908.25
9,520.8
9,259.86
9,692.11
10,127.45
10,429.63
11,247.44
11,642.95
13,031.49
15,089.09
16,998.69
16,087.92
15,448.7
Basic EPS, GAAP
955
1,232
1,343
1,074
1,780
1,409
1,225
1,532
1,746
1,567
1,950
1,531
857
1,155.36
Free Cash Flow per Basic Share
618.12
96.46
823.58
809.67
272.94
842.28
1,422.87
951.85
2,001.18
-3,334.78
-543.08
-568.9
180.36
838.28
Dividend per Share
250
250.05
249.93
249.99
250.03
299.91
300.1
300.02
299.96
300.03
299.96
299.91
288.72
- -
Book Value per Share
11,345.37
12,348.24
13,532.02
14,418.57
15,922.08
17,002.9
17,932.54
19,395.66
20,759.68
21,845.15
23,462.75
24,628.27
22,776.9
23,018.54
Tangible Book Value per Share
11,097.14
12,231.27
13,387.71
14,337.54
15,806.63
16,847.16
17,728.52
19,199.97
20,565.2
21,637.11
23,110.24
24,159.27
22,274.17
22,527.1
Basic Weighted Avg Shares
15
15
15
15
15
15
15
15
15
15
15
15
16
18
Sales/Revenue/Turnover
104,480
120,713
145,397
141,376
147,953
154,664
159,177
171,705
177,776
198,935
230,394
259,596
255,214
273,474
Operating Margin (%)
19.29
19.89
17.48
15.3
20.04
17.68
16.44
16.55
17.59
14.99
13.1
8.28
5.1
8.16
Depreciation Expense
1,716
1,890
1,917
2,021
2,287
3,148
3,900
4,070
4,202
4,847
6,659
8,475
9,865
9,845
Net Income, GAAP
14,580
18,806
20,510
16,397
27,172
21,518
18,696
23,388
26,660
23,921
29,774
23,381
13,595
20,452
Effective Tax Rate (%)
31.97
22.28
22.95
24.75
25.5
26.62
34.05
25.39
21.91
20.38
11.89
13.23
8.92
19.97
Profit Margin (%)
13.95
15.58
14.11
11.6
18.37
13.91
11.75
13.62
15
12.02
12.92
9.01
5.33
7.48
Working Capital
129,012
132,608
132,666
143,388
143,827
164,177
180,233
187,630
211,512
165,671
172,074
158,921
171,769
183,733
LT Debt
- -
- -
- -
- -
- -
- -
1,134
1,643
1,305
64
307
136
282
157
Total Equity
173,210
188,522
206,594
220,129
243,084
259,584
274,461
296,602
317,226
333,928
358,207
376,002
421,007
425,474
Return on Invested Capital (%)
7.99
10.07
9.67
7.46
9.29
7.77
6.31
7.24
7.77
7.2
7.67
5.09
2.97
4.44
Return on Capital (%)
8.69
10.4
10.38
7.69
11.73
8.56
7.02
8.21
8.71
7.4
8.6
6.37
3.41
5.07
Return on Common Equity (%)
8.69
10.4
10.38
7.69
11.73
8.56
7.01
8.21
8.7
7.36
8.61
6.37
3.41
5.08

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
397
361
411
LT Borrowings
- -
- -
- -
LT Finance Leases
282
218
157
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
209,238
189,830
179,664

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
228,271
232,371
240,136
Cash, Cash Equivalents & STI
63,720
63,617
66,642
Accounts Receivable, Net
61,876
62,981
66,419
Inventories
96,322
95,390
100,376
Total Current Liabilities
56,501
56,679
56,403
Payables & Accruals
- -
- -
- -
ST Debt
397
361
411
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.4%
7.29%
11.97%
Free Cash Flow
-19.17%
-73.64%
-132.93%
Net Income, GAAP
0.17%
-7.03%
-41.85%
Sales/Revenue/Turnover
5.95%
8.45%
-1.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
61,610
63,619
68,113
66,253
259,596
2025
60,199
64,135
65,736
65,144
255,214
2026
71,176
71,418
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
594
407
296
234.77
1,531
2025
335
209
202.32
113.85
857
2026
403.91
417
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
299.91
2025
- -
- -
- -
- -
288.72
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wonbum Lee
Full Time Employees
671
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Whanin Building, 11 Seoul SL South Korea 05855
IPO Date
Jul 3, 1996
Website
whanin.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Whan In Pharm Co., Ltd. manufactures and markets prescription pharmaceuticals primarily in South Korea, with a focus on central nervous system (CNS) drugs including anti-psychotics, anti-depressants, anti-epileptics, anti-dementia agents, and nootropics; cardiovascular treatments; gastrointestinal medications; analgesics and anti-inflammatories; antibiotics; antivirals; antihistamines; metabolic disorder therapies; respiratory products; osteoporosis preventives; and ulcer and liver protection drugs. Founded in 1978 and headquartered in Seoul's Songpa-gu district, the company generates the majority of its revenue from ethical drugs in the domestic market, supplemented by minor over-the-counter and other segments, while also engaging in real estate leasing. In recent years, Whan In Pharm has pursued production expansion through a proposed new facility at its Hwaseong plant to enhance manufacturing capacity for antibiotics, cardiovascular drugs, multivitamins, and other lines, alongside ongoing R&D investments in CNS innovations via connect-and-develop strategies, joint ventures, and global market entry preparations for generics and incrementally modified drugs.